NAD+ therapy claims on TikTok: what the science actually supports

What did @novaura2025 actually say?

Honestly, this is a difficult video to fact-check in the traditional sense, because the transcript is largely incoherent. The caption does the heavy lifting, claiming NAD+ therapy "repairs, rejuvenates, and replenishes your body at a cellular level" and supports "anti-ageing by promoting cellular repair and regeneration." The video itself appears to be a client testimonial, with a person named Amy describing improvements in energy levels and enthusiasm for the service. The actual spoken content is fragmented and includes references to "metabolic issues," "cardio," and "energy levels," but no specific medical claims are made coherently on camera.

What we can fact-check is the caption's written claims, which are the promotional statements a viewer would actually read and act on.

Does the science back this up?

NAD+ (nicotinamide adenine dinucleotide) is a real coenzyme with a real role in cellular metabolism. The anti-ageing angle, however, is considerably more speculative than this video implies.

Here is what the evidence actually shows:

• NAD+ levels do decline with age in human tissue. That part is well-established (Yoshino et al., 2018, Cell Metabolism).
• Precursor supplementation, particularly NMN and NR, raises circulating NAD+ levels in humans. Multiple small trials confirm this (Elhassan et al., 2019, Cell Reports).
• Whether raising NAD+ through IV infusion translates into meaningful anti-ageing outcomes in healthy humans is a different question entirely, and one without strong clinical trial evidence to date.
• Most of the compelling longevity data comes from animal models, not human RCTs. Translating mouse studies to human outcomes has a poor track record in this space.

The claim that IV NAD+ "promotes cellular repair and regeneration" is plausible at the mechanistic level, since NAD+ feeds into PARP and sirtuin pathways involved in DNA repair. But plausible mechanism is not the same as proven clinical outcome. Reviewers including Covarrubias et al. (2021, Nature Reviews Molecular Cell Biology) note the human evidence remains preliminary.

What did they get wrong (or right)?

To give credit where it is due: NAD+ is not snake oil. The underlying biology is legitimate, and interest from serious researchers is real. If Amy reported improved energy after infusions, that is consistent with anecdotal reports in the literature, even if the mechanism is not fully understood.

What this video gets wrong, or at minimum overstates, is the certainty of the benefit. Saying NAD+ therapy "plays a vital role in supporting holistic health" positions an unproven intervention as established medicine. It is not. The caption's framing implies clinical-grade evidence for outcomes that are, at best, supported by early-phase trials and mechanistic inference.

There is also no disclosure about risks. IV NAD+ infusions are not risk-free. Reported side effects include nausea, flushing, chest tightness, and headache during infusion. These are well-documented in clinical settings. A promotional testimonial video with no mention of adverse effects or the need for medical screening is incomplete at best.

The testimonial format itself is a regulatory concern. Using a client's reported experience to imply clinical efficacy is the kind of marketing that sits uncomfortably close to therapeutic claims under Australian advertising standards.

What should you actually know?

If you are considering NAD+ IV therapy, here is the honest summary of where things stand.

NAD+ infusions are administered in clinical settings across Australia and the US. They are not approved by the TGA or FDA for any specific indication, which means their use is off-label and the evidence base is still developing. That does not make them automatically unsafe, but it does mean the burden of proof for the claims being made in promotional content has not been met yet.

Oral NAD+ precursors like NMN and NR have a more developed human trial record for raising NAD+ levels and are considerably cheaper. Whether IV delivery offers a meaningful advantage over oral precursors in healthy adults has not been demonstrated in head-to-head trials.

If you are drawn to this therapy, the reasonable approach is a conversation with a physician who can assess whether you have any underlying metabolic or mitochondrial condition that might make NAD+ support appropriate, rather than booking based on a TikTok testimonial.

• Ask about the evidence base for your specific concern, not anti-ageing in general.
• Ask what monitoring is in place during the infusion.
• Ask whether oral precursors have been considered first.
• Be skeptical of any provider who cannot answer these questions clearly.